Quanterix Corp (QTRX) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Latest close $2.07 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold QTRX. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
WATERS CORP /DE/ (WAT) · Avantor, Inc. (AVTR) · BIO-RAD LABORATORIES, INC. (BIO) · AGILENT TECHNOLOGIES, INC. (A) · ILLUMINA, INC. (ILMN) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | 0.02% | 2,753,165 | ADDED (+111.8%) Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -34.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 133 of 8,857 filers |
| Long-only filers among them | 132 |
| Change vs 2026 Q1 | +10 net · 133 entered · 123 exited |
| Shares reported, all filers | 29,416,110 |
| Reported value, all filers | $126.1M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments (SIC 3826) |
| Revenue · FY2025 | $138.9M |
| Net income · FY2025 | $-107.2M |
| Total assets · FY2025 | $418.8M |
| Shares outstanding | 47,293,065 |
| Market cap (at latest close) | $97.9M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Oct 15, 2026 | 4,678,542 |
| Share of shares outstanding | 9.89% |
| Days to cover | 8.41 |
Shares short at recent settlements — Jul 31, 2026: 4.5M · Aug 14, 2026: 4.7M · Aug 31, 2026: 4.8M · Sep 15, 2026: 5.0M · Sep 30, 2026: 5.0M · Oct 15, 2026: 4.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 10K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jun 12, 2024 | LAURIE OLSON | Director | 20,915 | $378.1K | Jun 12, 2024 | SEC filing |
| Apr 1, 2024 | LAURIE OLSON | Director | 1,000 | $23.5K | Apr 1, 2024 | SEC filing |
| Feb 14, 2024 | LAURIE OLSON | Director | 1,500 | $36.5K | Feb 14, 2024 | SEC filing |
| Jan 2, 2024 | LAURIE OLSON | Director | 1,000 | $26.9K | Jan 2, 2024 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jul 15, 2025 | SCHEDULE 13D/A | -49.5% (close Jul 16, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jul 16, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Portolan Capital Management, LLC | SC 13G/A | 1,899,308 | 4.0% | Jun 30, 2026 | SEC filing |
| Aug 6, 2026 | First Eagle Investment Management, LLC | SC 13G | 2,753,165 | 5.8% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | Ameriprise Financial, Inc. | SC 13G/A | 3,542,374 | 7.5% | Mar 31, 2026 | SEC filing |
| May 15, 2026 | Portolan Capital Management, LLC | SC 13G/A | 2,945,823 | 6.2% | Mar 31, 2026 | SEC filing |
| May 7, 2026 | Ameriprise Financial, Inc. | SC 13G/A | 990,224 | 2.1% | Apr 30, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | Ameriprise Financial, Inc. | SC 13G/A | 4,996,073 | 10.7% | Dec 31, 2025 | SEC filing |
| Nov 19, 2025 | Telegraph Hill Partners III, L.P. | SC 13G | 2,504,648 | 5.4% | Sep 30, 2025 | SEC filing |
| Nov 14, 2025 | Ameriprise Financial, Inc. | SC 13G/A | 4,243,512 | 9.1% | Sep 30, 2025 | SEC filing |
| Aug 13, 2025 | Portolan Capital Management, LLC | SC 13G/A | 3,633,622 | 9.4% | Jun 30, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Laboratory Analytical Instruments (SIC 3826). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).
Federal contracts: $3.5M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $1.9M |
| FY2022 | $657.7K |
| FY2023 | $414.7K |
| FY2024 | $388.4K |
| FY2025 | $210.3K |
| FY2026 | $-59.0K |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 75N92020C00035 | Department of Health and Human Services | $18.2M | Sep 29, 2020 |
| 36C24E21N0113 | Department of Veterans Affairs | $436.5K | Jul 15, 2021 |
| 36C24824P0467 | Department of Veterans Affairs | $251.9K | Dec 21, 2023 |
| 36C24E22N0135 | Department of Veterans Affairs | $223.2K | Jul 15, 2022 |
| 75N95023P00394 | Department of Health and Human Services | $198.0K | Jun 27, 2023 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Red Flags
· Earnings Manipulation Suspect (Beneish) — Beneish M-Score above -1.78
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Financial Restatement (8-K 4.02) — Last 3 years: a non-reliance / restatement filing (8-K Item 4.02)
· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)
· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)
Key figures
· Earnings Manipulation Suspect (Beneish) — M-Score: -0.62 · Receivables index: 0.92 · Margin deterioration: 1.29 · Sales growth index: 1.01 · Accruals ratio: -7.1%
· Distress Risk (Altman Z″) — Z″-Score: -1.83 · Working capital / assets: 0.33 · Retained earnings / assets: -1.38 · EBIT / assets: -0.30 · Equity / liabilities: 2.40
· Financial Restatement (8-K 4.02) — Latest event: Nov 12, 2024 · Events in 3 yrs: 1
· Auditor Change (8-K 4.01) — Latest event: May 14, 2025 · Events in 2 yrs: 1
· Late Filings (NT) — Latest event: Nov 13, 2024 · Events in 2 yrs: 1 · Latest form: NT 10-Q
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 3 of the last 20 quarterly lists; latest 2025 Q2, ranked #32 of 50.
Also held by the tracked funds that hold QTRX — ranked by lift, the co-holding pattern described in Methodology: WATERS CORP /DE/ (WAT) · Avantor, Inc. (AVTR) · BIO-RAD LABORATORIES, INC. (BIO) · AGILENT TECHNOLOGIES, INC. (A) · ILLUMINA, INC. (ILMN) · METTLER TOLEDO INTERNATIONAL INC/ (MTD) · BRUKER CORP (BRKR) · 908 Devices Inc. (MASS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 18, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 9, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 10, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
WATERS CORP /DE/ (WAT) · Track Record: how the signals scored · Practice timing on QTRX
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.